BOSTON--(BUSINESS WIRE)--BPGbio, Inc., the leading biology-first AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the addition of Kenin M. Spivak, a highly regarded executive, entrepreneur, financier, author, and attorney to its Board of Directors, as an independent director..

波士顿-（商业线）-BPGbio，Inc.，领先的生物学第一个人工智能生物制药，专注于肿瘤学，神经病学和罕见疾病，今天宣布增加备受瞩目的高管，企业家，融资人员Kenin M.Spivak，其董事会作者和律师兼独立董事。。

“We are thrilled to welcome Kenin Spivak to the BPGbio Board,” said Daniel Elliott, Executive Chairman of BPGbio. “Kenin’s wealth of experience in multi-disciplinary business fields and expertise in corporate governance are invaluable assets to BPGbio as we as grow our business to the next level by advancing our late-stage therapeutic pipeline and strategic partnerships.”.

BPGbio执行主席丹尼尔·埃利奥特（Daniel Elliott）说：“我们很高兴欢迎Kenin Spivak加入BPGbio董事会。”。“随着我们通过推进后期治疗渠道和战略合作伙伴关系将业务发展到下一级，凯宁在多学科业务领域和公司治理专业知识方面的丰富经验对BPGbio来说是宝贵的资产。”。

Mr. Spivak is the founder, chairman and CEO of SMI Group LLC and chairman of its operating units. Prior to SMI Group, Mr. Spivak led multi-national companies with billions of dollars of worldwide sales and operations in more than 30 countries, including serving as CEO of a News Corporation affiliate, a wireless technology company, and distribution companies, principal operating officer of major studio MGM/UA, founding chairman of the Paul Mitchell cosmetology schools, and an officer and director of Merrill Lynch media and entertainment partnerships.

Spivak先生是SMI Group LLC的创始人，主席兼首席执行官以及其运营部门主席。在SMI集团之前，Spivak先生领导了跨国公司，在30多个国家/地区拥有数十亿美元的全球销售和运营，其中包括担任无线技术公司新闻公司附属公司的首席执行官，以及分销公司，首席运营官。major studio MGM/UA，Paul Mitchell美容学校创始主席，以及Merrill Lynch媒体和娱乐合作伙伴关系的官员兼董事。

He has served as a director of, and advisor to, several healthcare and technology companies..

他曾担任多家医疗保健和技术公司的董事和顾问。。

“BPGbio is greatly accelerating the development of new therapeutics and diagnostics by uniting its pioneering scientific team, the nation’s leading biobank, and cutting-edge AI capabilities,' said Mr. Spivak, adding, “I am honored to join the board and look forward to supporting BPG’s development and commercialization of its late-stage assets.”.

Spivak先生补充说：“BPGbio通过联合其开创性的科学团队，国家领先的生物库和尖端的人工智能能力，极大地加速了新疗法和诊断技术的开发。”我很荣幸加入董事会并期待支持BPG后期资产的开发和商业化“。

Mr. Spivak received A.B., M.B.A. and J.D. degrees from Columbia University, each with honors, completing all three degrees in six years. He is admitted to practice law in California and New York, and holds numerous securities licenses, including Series 24 (general securities principal).

Spivak先生获得哥伦比亚大学的A.B.，M.B.A.和J.D.学位，每个学位均获得荣誉，并在六年内完成所有三个学位。他获准在加利福尼亚州和纽约执业，并拥有众多证券许可，包括第24系列（通用证券委托人）。

BPGbio's therapeutic pipeline, developed from the company’s NAi Interrogative Biology® Platform, includes therapeutic candidates being studied for glioblastoma multiforme (GBM) in active phase 2b, pancreatic cancer in phase 2a, epidermolysis bullosa (EB), squamous cell carcinoma (SCC), sarcopenia, solid and liquid tumors, Huntington’s disease, Parkinson's disease, and diabetes type II.

BPGbio的治疗管道由该公司的NAi询问生物学平台开发，包括正在研究活动期2b多形性胶质母细胞瘤（GBM），2a期胰腺癌，大疱性表皮松解症（EB），鳞状细胞癌（SCC），肌肉减少症，实体和液体肿瘤，亨廷顿舞蹈病，帕金森病和II型糖尿病。

The company's diagnostic pipeline includes its prostate diagnostic panel pstateDx, as well as tests being developed and validated for the detection of Parkinson’s disease, pancreatic cancer, breast cancer and liver disease..

该公司的诊断管道包括其前列腺诊断小组pstateDx，以及正在开发和验证用于检测帕金森病，胰腺癌，乳腺癌和肝病的测试。。

About BPGbio, Inc.

关于BPGbio公司。

BPGbio is the leading biology-first AI-powered clinical stage biopharma and diagnostics company focused on oncology, neurology and rare diseases. The company has a deep portfolio of AI-developed pipeline of therapeutics, including several in late-stage development. BPGBio’s novel approach is underpinned by NAI, its proprietary Interrogative Biology Platform, protected by over 450 US and international patents; the world's largest clinically annotated non-governmental biobank; and exclusive access to the most powerful supercomputer in the world.

BPGbio是领先的生物学第一人工智能临床阶段生物制药和诊断公司，专注于肿瘤学，神经病学和罕见疾病。该公司拥有一套由人工智能开发的治疗管道组成的深层产品组合，其中包括几个处于后期开发阶段的产品。BPGBio的新方法以其专有的询问生物学平台NAI为基础，受到450多项美国和国际专利的保护；世界上最大的临床注释非政府生物库；并独家访问世界上最强大的超级计算机。

With these tools, BPGbio is redefining how patient biology can be modeled using unbiased AI. Headquartered in Boston, the company is at the forefront of a new era in medicine, combining biology, data, and AI to transform the way disease is diagnosed and treated. For more information, visit www.bpgbio.com..

利用这些工具，BPGbio正在重新定义如何使用无偏AI对患者生物学进行建模。总部设在波士顿，该公司处于医学新时代的前沿，将生物学，数据和AI相结合，以改变疾病的诊断和治疗方式。欲了解更多信息，请访问www.bpgbio.com。。